Dendrimers and their applications in biomedicine: Dendrimer-drug interaction, a new therapeutic alternative

Buitrago, M. de la Sierra Espinar; Fernández, M. Ángeles Muñoz

doi:10.1016/b978-0-12-821250-9.00019-6

Cited by 3 publications

(1 citation statement)

References 147 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, dendrimer-based molecules have been recognized as an effective immunotherapy for viral infections, cancer, and autoimmune diseases due to their ability to efficiently capture and load antigens, their biocompatibility, and their versatility in various therapeutic applications [12]. Specifically, polyanionic carbosilane dendrimers (PCDs) have shown their ability to prevent the transmission of several sexually infectious diseases, such as Human Immunodeficiency Virus (HIV-1), Human Herpes Virus type 1 or 2 (HSV-1/HSV-2) or Hepatitis C Virus (HCV) [13][14][15], and even HCMV, as we have previously demonstrated [16].…”

Section: Introductionmentioning

confidence: 99%

Enhanced Immunomodulatory Effects of Thymosin-Alpha-1 in Combination with Polyanionic Carbosilane Dendrimers against HCMV Infection

Espinar-Buitrago,

Magro-López,

Vázquez-Alejo

et al. 2024

IJMS

View full text Add to dashboard Cite

Resistance and toxicity associated with current treatments for human cytomegalovirus (HCMV) infection highlight the need for alternatives and immunotherapy has emerged as a promising strategy. This study examined the in vitro immunological effects of co-administration of Thymosin-alpha-1 (Tα1) and polyanionic carbosilane dendrimers (PCDs) on peripheral blood mononuclear cells (PBMCs) during HCMV infection. The biocompatibility of PCDs was assessed via MTT and LDH assays. PBMCs were pre-treated with the co-administered compounds and then exposed to HCMV for 48 h. Morphological alterations in PBMCs were observed using optical microscopy and total dendritic cells (tDCs), myeloid dendritic cells (mDCs), and plasmacytoid dendritic cells (pDCs), along with CD4+/CD8+ T cells and regulatory T cells (Treg), and were characterized using multiparametric flow cytometry. The findings revealed that Tα1 + PCDs treatments increased DC activation and maturation. Furthermore, increased co-receptor expression, intracellular IFNγ production in T cells and elevated Treg functionality and reduced senescence were evident with Tα1 + G2-S24P treatment. Conversely, reduced co-receptor expression, intracellular cytokine production in T cells, lower functionality and higher senescence in Treg were observed with Tα1 + G2S16 treatment. In summary, Tα1 + PCDs treatments demonstrate synergistic effects during early HCMV infection, suggesting their use as an alternative therapeutic for preventing virus infection.

show abstract